Share on LinkedInShare on LinkedIn

ARTICLE · 16 APRIL 2015

GSK-Novartis Transaction Approved In Canada Based On Commitments In EU And US

Although only the OTC joint venture was notifiable under Part IX of the Competition Act, the Bureau conducted a full analysis on all three parts of the proposed transaction.

GlobalAntitrust/Competition Law

A proposed transaction between two multinational pharmaceutical and consumer healthcare product companies, GlaxoSmithKline (GSK) and Novartis was recently given the go-ahead by the Competition Bureau. The proposed transaction was announced on April 22, 2014 as a three-part, inter-conditional transaction, which involved the creation of a joint venture between GSK and Novartis for their over-the-counter (OTC) and consumer healthcare products. GSK would also acquire Novartis' global vaccine business, while Novartis would acquire GSK's portfolio of oncology products. Undertakings given by GSK to EU and US competition agencies dispelled the Bureau's concerns that some aspects of the transaction could lessen competition.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from